MALVERN, Pennsylvania & BRISBANE, Australia–(BUSINESS WIRE)–Alliance Pharma (Alliance), a global leader in bioanalytical and CMC testing services to the pharmaceutical and biopharmaceutical industry, today announced the opening of a bioanalytical laboratory, Alliance Pharma Pty, Ltd., in Brisbane , in Australia. The purpose-built 20,000 square foot facility to support preclinical and clinical testing will be fully operational in November 2022.
Alliance Pharma Pty, Ltd. will contain an extensive state-of-the-art laboratory, providing much-needed small and large molecule bioanalytical services for a region that currently has limited choices for bioanalytical support. Alliance will now also be able to transfer methods and maintain ongoing project management at its global bioanalytical sites in the United States and Europe. The opening of the Australian site by Alliance closely follows their recent acquisition of UK-based Drug Development Solutions (DDS) from LGC.
“With the rapid start-up of phase I studies, the quality of clinical sites and a favorable Australian R&D tax credit, Australia is an optimal market for early phase clinical research,” said Alliance CCO Vito Saccente. “Alliance will not only be able to provide critical services to this market, but also when these compounds move into Phase II, we will be well positioned to transfer methods without losing critical knowledge and we can continue to support the progression of clinical development.” of our customers. .”
Alliance Pharma Pty, Ltd. President Hao (Jason) Wang, Ph.D., will lead a team of experienced scientists to provide a broad range of bioanalytical services. This new laboratory is equipped with the latest LC-MS, ligand binding, flow cytometry, ELISpot and PCR instruments to support early and late phase research and will be capable of de novo method development, method transfers, method validation and sample analysis for pharmacokinetics (PK), biomarkers and immunogenicity.
About Alliance Pharma
Founded in 2008, Alliance is a contract research organization (CRO) with bioanalytical and CMC testing laboratories in Malvern, PA, Brisbane, AU, Cambridge, UK and Sandwich, UK. The laboratories specialize in advanced research services for all drug molecules, cell and gene therapies, and drug metabolism studies to support the drug discovery and development programs of pharmaceutical and biotechnology companies. Alliance’s mission is to build a trusted partnership with our customers to support their successful drug development programs. Our business philosophy is based on trust, professional ethics, scientific excellence and regulatory compliance.